Guangzhou Huajin Pharmaceutical Technology

Guangzhou Huajin Pharmaceutical Technology is a clinical-stage biopharmaceutical company focused on developing innovative enzyme replacement therapies for metabolic and rare diseases. The company's core expertise lies in its proprietary PEGylation technology platform, which it uses to optimize the pharmacological properties of therapeutic proteins. Its lead candidate, HJ001, is a pegylated recombinant uricase currently in Phase 2 clinical trials for the treatment of chronic refractory gout. Additionally, the company is advancing a pipeline of biologics targeting oncology indications, such as HJ002 for arginine-dependent tumors. Based in Guangzhou, China, Huajin aims to provide high-quality, affordable biological drugs for patients with significant unmet medical needs. The company has secured funding from prominent Chinese investors to support its clinical development programs.